News >

FDA Grants Breakthrough Designation to Frontline Enfortumab Vedotin/Pembrolizumab in Bladder Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 19, 2020

The FDA has granted a breakthrough therapy designation to the combination of enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) as a first-line treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication